273 related articles for article (PubMed ID: 15998357)
1. Comparison of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) as inhibitors of cytochrome P450 2C8.
Tornio A; Pasanen MK; Laitila J; Neuvonen PJ; Backman JT
Basic Clin Pharmacol Toxicol; 2005 Aug; 97(2):104-8. PubMed ID: 15998357
[TBL] [Abstract][Full Text] [Related]
2. Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport.
Sakaeda T; Fujino H; Komoto C; Kakumoto M; Jin JS; Iwaki K; Nishiguchi K; Nakamura T; Okamura N; Okumura K
Pharm Res; 2006 Mar; 23(3):506-12. PubMed ID: 16388406
[TBL] [Abstract][Full Text] [Related]
3. Examination of 209 drugs for inhibition of cytochrome P450 2C8.
Walsky RL; Gaman EA; Obach RS
J Clin Pharmacol; 2005 Jan; 45(1):68-78. PubMed ID: 15601807
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions.
Shitara Y; Sugiyama Y
Pharmacol Ther; 2006 Oct; 112(1):71-105. PubMed ID: 16714062
[TBL] [Abstract][Full Text] [Related]
5. Small intestinal metabolism of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor lovastatin and comparison with pravastatin.
Jacobsen W; Kirchner G; Hallensleben K; Mancinelli L; Deters M; Hackbarth I; Baner K; Benet LZ; Sewing KF; Christians U
J Pharmacol Exp Ther; 1999 Oct; 291(1):131-9. PubMed ID: 10490896
[TBL] [Abstract][Full Text] [Related]
6. Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations.
Prueksaritanont T; Ma B; Tang C; Meng Y; Assang C; Lu P; Reider PJ; Lin JH; Baillie TA
Br J Clin Pharmacol; 1999 Mar; 47(3):291-8. PubMed ID: 10215754
[TBL] [Abstract][Full Text] [Related]
7. Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver.
Jacobsen W; Kirchner G; Hallensleben K; Mancinelli L; Deters M; Hackbarth I; Benet LZ; Sewing KF; Christians U
Drug Metab Dispos; 1999 Feb; 27(2):173-9. PubMed ID: 9929499
[TBL] [Abstract][Full Text] [Related]
8. Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes.
Cohen LH; van Leeuwen RE; van Thiel GC; van Pelt JF; Yap SH
Biopharm Drug Dispos; 2000 Dec; 21(9):353-64. PubMed ID: 11523064
[TBL] [Abstract][Full Text] [Related]
9. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
10. Cytochrome P450 2C8 (CYP2C8)-mediated hydroxylation of an endothelin ETA receptor antagonist in human liver microsomes.
Ma B; Subramanian R; Schrag ML; Rodrigues AD; Tang C
Drug Metab Dispos; 2004 May; 32(5):473-8. PubMed ID: 15100167
[TBL] [Abstract][Full Text] [Related]
11. Profiling induction of cytochrome p450 enzyme activity by statins using a new liquid chromatography-tandem mass spectrometry cocktail assay in human hepatocytes.
Feidt DM; Klein K; Hofmann U; Riedmaier S; Knobeloch D; Thasler WE; Weiss TS; Schwab M; Zanger UM
Drug Metab Dispos; 2010 Sep; 38(9):1589-97. PubMed ID: 20551241
[TBL] [Abstract][Full Text] [Related]
12. Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies.
Pasha MK; Muzeeb S; Basha SJ; Shashikumar D; Mullangi R; Srinivas NR
Biomed Chromatogr; 2006 Mar; 20(3):282-93. PubMed ID: 16143964
[TBL] [Abstract][Full Text] [Related]
13. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions.
Fischer V; Johanson L; Heitz F; Tullman R; Graham E; Baldeck JP; Robinson WT
Drug Metab Dispos; 1999 Mar; 27(3):410-6. PubMed ID: 10064574
[TBL] [Abstract][Full Text] [Related]
14. Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants.
Melet A; Marques-Soares C; Schoch GA; Macherey AC; Jaouen M; Dansette PM; Sari MA; Johnson EF; Mansuy D
Biochemistry; 2004 Dec; 43(49):15379-92. PubMed ID: 15581350
[TBL] [Abstract][Full Text] [Related]
15. Effect of atorvastatin and fluvastatin on the metabolism of midazolam by cytochrome P450 in vitro.
Mc Donnell CG; Shorten G; Van Pelt FN
Anaesthesia; 2005 Aug; 60(8):747-53. PubMed ID: 16029222
[TBL] [Abstract][Full Text] [Related]
16. Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics.
Neuvonen PJ
Curr Opin Investig Drugs; 2010 Mar; 11(3):323-32. PubMed ID: 20178046
[TBL] [Abstract][Full Text] [Related]
17. Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions.
Ogilvie BW; Zhang D; Li W; Rodrigues AD; Gipson AE; Holsapple J; Toren P; Parkinson A
Drug Metab Dispos; 2006 Jan; 34(1):191-7. PubMed ID: 16299161
[TBL] [Abstract][Full Text] [Related]
18. Apoptotic injury in cultured human hepatocytes induced by HMG-CoA reductase inhibitors.
Kubota T; Fujisaki K; Itoh Y; Yano T; Sendo T; Oishi R
Biochem Pharmacol; 2004 Jun; 67(12):2175-86. PubMed ID: 15163549
[TBL] [Abstract][Full Text] [Related]
19. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update.
Schachter M
Fundam Clin Pharmacol; 2005 Feb; 19(1):117-25. PubMed ID: 15660968
[TBL] [Abstract][Full Text] [Related]
20. Functional characterization of CYP2C8.13 and CYP2C8.14: catalytic activities toward paclitaxel.
Hanioka N; Matsumoto K; Saito Y; Narimatsu S
Basic Clin Pharmacol Toxicol; 2010 Jul; 107(1):565-9. PubMed ID: 20148860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
